Zelira Therapeutics has announced the University of Western Australia team that undertook a double-blind, placebo-controlled, crossover trial of its ZTL-101 (Zenivol) treatment for chronic insomnia patients has had the results published in peer-reviewed journal Sleep.

The results of the trial, undertaken at the university’s Centre for Sleep Science and published earlier this year, showed patients saw a significant decrease in insomnia after using Zenivol for two weeks relative to a placebo. Chronic insomnia is present in six to 15% of the population.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Elementum integer enim neque volutpat ac tincidunt vitae semper quis. Eu lobortis elementum nibh tellus molestie nunc. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Magnis dis parturient montes nascetur ridiculus. Dui id ornare arcu odio ut sem. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment